A franchiseable luxury medical-spa brand built on a defensible AI-diagnostics and outcomes-data moat. Flagship in the Bal Harbour / North Miami corridor; a sunbelt-first national franchise roadmap.
Most med spa franchises compete on brand and buying power alone - copyable within a year. SPUR MediSpa's edge is structural: proprietary AI diagnostics fed by multi-location outcomes data (running on SPUR's own GPU fleet) plus medical-director-and-compliance-as-a-service for franchisees - the two hardest things in this business. Prove the model at a Bal Harbour-corridor flagship (months 0-12), then franchise sunbelt-first (Florida, then GA/AZ for the cleanest legal path). Franchisor revenue is asset-light: ~8-9% of every unit's gross plus group-purchasing margin.
SPUR MediSpa is a luxury medical-spa brand designed from day one to franchise. The US med spa market is ~$6.9B (2024), growing ~14% annually toward ~$17.6B by 2030, and is 81% single-location independents - a fragmented field ideal for a branded roll-up. The average location does ~$1.4M revenue at 20-25% margins.
The company proves the concept at a corporate flagship in the Bal Harbour / North Miami corridor (one of the densest concentrations of ultra-wealth in the US), then sells franchises sunbelt-first. The defensible advantage is not brand or Botox - those are copyable - but two things SPUR is uniquely positioned to own: (1) proprietary AI diagnostics + multi-location outcomes data on SPUR's GPU infrastructure, and (2) medical-director / compliance-as-a-service that solves the single hardest part of opening a med spa in every state.
Franchisor economics are capital-light: a ~$50k franchise fee, 6-7% royalty, 2-3% brand fund, plus group-purchasing margin - roughly 8-9% of every franchisee's gross flows to the franchisor, who carries almost no per-unit capex. Franchised brands trade at >6x EBITDA vs 3-5x for a single studio.
The field splits into VC-backed corporate chains, a handful of franchises, and a long tail of ~81% independents. None pairs a luxury brand with a genuine data/AI moat plus turnkey medical compliance - the white space SPUR targets.
| Player | Model | Focus | Gap SPUR exploits |
|---|---|---|---|
| VIO Med Spa | Franchise (~$0.8-1.3M/unit) | Injectables + IV + aesthetics | No proprietary AI/data; generic protocols |
| Restore Hyper Wellness | Franchise (rapid) | Cryo, IV, hyper-wellness | 18 closures in 2024 - weak unit quality control |
| Glo30 | Franchise ($180k dev fee) | Membership skincare | Skin-only; no medical depth (GLP-1 / BHRT) |
| SEV Laser | Corporate rollout | Laser hair removal, price-led | Commodity service; no luxury / longevity tier |
| Ever/Body, Skin Laundry | VC-backed corporate | Urban aesthetics chains | Capital-heavy; no franchise leverage; coastal-only |
| ~81% independents | Single location | Owner-operated | No brand, buying power, compliance scale or data |
Positioning: SPUR is the only entrant combining a defensible AI / data moat, compliance-as-a-service and a recurring longevity / hormone core in a franchiseable luxury format - aimed at under-saturated sunbelt wealth, not the crowded coastal corporate markets.
Most med spa franchises have weak moats - brand and buying power are real but copyable. SPUR MediSpa concentrates on the few things that compound and resist copying. Ranked by defensibility:
Years of paired before/after images linked to exact treatment parameters cannot be scraped or back-filled. SPUR's own GPU fleet fine-tunes models on a corpus no rival has. The data is the moat - not the off-shelf cameras.
Every franchise feeds one shared model; a networked system improves roughly 2x faster than any solo. The network itself is the barrier - a single clinic can never assemble a multi-site outcomes corpus.
50-state corporate-practice-of-medicine / MSO structuring, a physician-director network, and audit discipline are existential and hard - and far cheaper per unit at scale. This is the service franchisees most need and can least do alone.
The injector shortage is the real scaling bottleneck. An owned academy creates a captive, standardized, brand-loyal supply of NP/PA injectors and estheticians.
Members carry ~3.5x LTV and 78% less churn - real switching costs - but the membership playbook itself is public. Defensible as a wrapper, not a standalone moat.
GPO discounts, device deals and booking/EHR software are real margin levers but matchable off-the-shelf. They fund the flywheel; they don't defend it.
The moats above are generic to "a well-run med spa franchise." SPUR can build them faster and cheaper than anyone because the hard infrastructure already exists in-house:
Commodity Botox is a loss-leader; the brand is built on sticky, high-margin, hard-to-copy services. Acquisition leaders (GLP-1, AI skin scan) feed the durable core (hormones, longevity, regenerative), all wrapped in concierge membership.
Semaglutide / tirzepatide programs, $250-$500/mo. The #1 acquisition + recurring-revenue engine.
$2,200-$3,500/yr. Biology forces quarterly, multi-year visits - the stickiest service in the book.
$500-$1,500/mo; $15-30k/yr LTV. Highest lifetime value, growing fastest.
$500-$2,500/session. A regulatory moat - the hardest service for a new entrant to launch correctly.
Morpheus8, Emface, Ellacor, Sofwave: $500-$6,000/session. Highest per-ticket; capex-gated.
The glue: free/low-cost AI scan converts walk-ins; membership ($99-$499/mo) wraps everything into ~3x LTV recurring revenue.
| Tier | Monthly | Included / month | Diagnostics | Discount |
|---|---|---|---|---|
| Glow | $99 | 1 facial / HydraFacial | Quarterly AI skin scan | 10% |
| Refine | $299 | Treatment credit + tox allowance | Monthly scan + dashboard | 15% + concierge |
| Icon | $499 | 2 treatments + larger tox allowance | Full diagnostic suite | 20% + priority/events |
| Term | SPUR MediSpa (proposed) | Industry benchmark |
|---|---|---|
| Franchise fee (single unit) | $55,000 | $50k-$80k |
| Royalty | 7% of gross (≥$3,500/mo from yr 2) | 6-7% |
| Brand / ad fund | 2% national + 1% local | 2-4% |
| Total investment / unit (luxury) | $750k-$1.2M | $777k-$1.32M (VIO/Restore) |
| Franchisee net worth / liquidity | $1.5M / $350k | $1.0-1.5M / $285-500k |
| Term | 10 years | 10 years |
| Multi-unit / area developer | 2-10 units; dev fee in lieu of per-unit fees | Glo30 $180k dev fee |
| Line | $ (000s) | % rev |
|---|---|---|
| Revenue | $2,350 | 100% |
| Cost of services (product, meds, consumables) | ($517) | 22% |
| Payroll incl. injectors | ($705) | 30% |
| Rent + CAM | ($144) | 6.1% |
| Local marketing | ($120) | 5.1% |
| Royalty (7%) + brand fund (3%) | ($235) | 10% |
| Tech, utilities, insurance, G&A | ($245) | 10.4% |
| Franchisee EBITDA (after fees) | +$384 | 16.3% |
Unit-level EBITDA before franchise fees is ~21-24% ($505k); ~$235k flows to the franchisor as royalty + brand fund, leaving the franchisee a healthy ~16% net - in range for a sustainable franchise.
| System | Avg unit gross | Royalty (6.5%) | + GPO & fees (est.) | Franchisor revenue |
|---|---|---|---|---|
| 10 units | $1.5M | $975k | $450k | ~$1.4M |
| 25 units | $1.7M | $2.76M | $1.1M | ~$3.9M |
| 50 units | $1.8M | $5.85M | $2.4M | ~$8.3M |
Franchisor EBITDA runs ~15-25% of royalty revenue after support cost - asset-light, since franchisees carry the build capex. Compliance note: MSO management fees must be flat / cost-plus (FMV), not a percentage of revenue, to satisfy anti-kickback / fee-splitting law - structure the medical layer separately from royalties with healthcare counsel.
Sunbelt-first rollout, biased to no-income-tax states with affluent, growing, under-saturated metros. Regulatory ease is a primary filter: Florida is the only state that permits direct non-physician ownership; Georgia and Arizona are low-barrier; Texas, Tennessee, Nevada, the Carolinas and California are strict corporate-practice-of-medicine (MSO required).
Interactive map - flagship in orange, Florida (easy regulatory) in green, moderate in amber, strict-CPOM markets in blue. Click a pin for detail.
Corporate flagship. Ultra-wealth catchment (Bal Harbour, Surfside, Sunny Isles, Aventura); S. Florida medspa ~20.7% CAGR.
Median HHI ~$153k; #3 US metro for millionaire concentration (~8.9%); pop +19.8%/decade; no income tax.
+112% millionaires 2014-24 (#4 globally); per-capita ~50% above US; no income tax.
~14,800 millionaires, +125% (fastest US wealth hub); flat 2.5% tax. Caveat: most saturated.
Collin County HHI $121.6k (2nd-wealthiest TX); #2 US county for growth; no income tax.
Williamson County HHI ~$133k (richest TN); least-saturated metro; no income tax.
~32,000 millionaires (+90%); best Texas whitespace; tech wealth; no income tax.
Buckhead 30327 ~9th-wealthiest US ZIP; flat 5.39% tax. Caveat: most saturated in SE.
ZIP 33606 has 32.7% of HH at $200k+; pop +18.7%/decade; no income tax.
City +12.3% since 2020 (fast growth); tax dropping 4.25%->3.99%. Aggressive CPOM enforcement.
Pop +24% since 2010; Summerlin/Henderson affluence + tourist spend; no income tax.
#1 US city for luxury ZIPs, but declining population + 13.3% top tax + strictest regime. Watch-list only.
The corporate flagship proves the model and seeds the data moat. A value-located storefront in the North Miami / Biscayne corridor serving the ultra-affluent catchment 5-10 minutes east (Bal Harbour, Surfside, Bay Harbor Islands, Indian Creek, Sunny Isles, Aventura). Open at ~$0.9-1.6M (lean injectables-first entry ~$400-600k); mature ~$2.35M revenue at ~21-24% EBITDA.
Do not run treatments from the Regus / Causeway Square serviced office (no per-room plumbing, no medical CO, no signage, HIPAA issues) - use it only as a virtual/admin address. Target ground-floor luxury-tower retail (Sunny Isles / Surfside / Bay Harbor) or a turnkey Aventura medical suite. Full single-site detail underpins the franchise unit model above.
| Use | Low | High |
|---|---|---|
| Medical buildout / construction (5 rooms) | $350k | $550k |
| Devices (laser, RF, body, diagnostics) | $300k | $500k |
| FF&E, design, branding | $120k | $180k |
| Licensing, legal, MSO setup | $50k | $90k |
| Working capital + pre-open marketing + staffing ramp | $150k | $250k |
| Flagship total | $0.97M | $1.57M |
| Use | Low | High |
|---|---|---|
| FDD, franchise + healthcare counsel, MSO architecture | $150k | $250k |
| AI diagnostics platform productization (on SPUR fleet) | $200k | $400k |
| Training academy + brand / ops playbook | $100k | $200k |
| Franchise sales + launch marketing | $100k | $200k |
| Franchisor infra total | $0.55M | $1.05M |
Franchisor reaches operating break-even at roughly 12-15 open units; thereafter royalty + GPO revenue scales asset-light. Much of the AI-platform spend is internal SPUR fleet cost rather than cash out the door, improving real capital efficiency.
| Year | Revenue | EBITDA (pre-royalty) |
|---|---|---|
| Year 1 (ramp) | $0.75M | -$135k |
| Year 2 | $1.68M | +$235k |
| Year 3 (mature) | $2.35M | +$505k (21.5%) |
| Phase | Timeline | Open units | Franchisor revenue |
|---|---|---|---|
| Flagship + proof | Yr 0-1 | 1 (corp) | - |
| FL franchise launch | Yr 1-2 | 3-5 | ~$0.6M |
| Sunbelt expansion | Yr 2-4 | 10-15 | ~$1.4-2.3M |
| National scale | Yr 4-6 | 25-50 | ~$3.9-8.3M |
Franchisor revenue = royalty (6.5%) + GPO margin + franchise/dev fees; EBITDA ~15-25% of royalty revenue. A 25-30% membership mix across the system adds ~0.5x-1.0x to the eventual exit multiple (franchised brands >6x EBITDA).
The defining med-spa landmine. Mitigation: build the MSO/PC + medical-director layer correctly with healthcare counsel before franchising; flat-fee MSO (never % of medical revenue); make compliance-as-a-service a core franchisor product.
Generic AI skin analysis is commoditizing; defensibility lives only in proprietary, outcome-linked, multi-year, multi-location data. Mitigation: mandatory standardized outcome capture from unit #1; tie franchise agreement to data contribution.
Roll-ups fail on inconsistent owners (Restore had 18 closures in 2024). Mitigation: strict franchisee selection, training academy, audits, protocol standardization.
NP/PA injectors are the scaling bottleneck. Mitigation: owned training academy as a moat + recruiting pipeline.
Scottsdale, Atlanta and Miami are competitive. Mitigation: differentiate on transparency + memberships + diagnostics; prioritize under-saturated wealth (Naples, Nashville/Franklin, Austin).
Devices are off-shelf; SPUR's own GPU fleet removes cloud-LLM cost and keeps the model in-house.